|
2011/12/02
Hiroyuki Abe, Shinichiro Akiyama
Kudan Clinic, Tokyo Japan
Abstract
Dendritic cell-based cancer vaccine (DC vaccine) is a highly personalized medicine in the sense of identification and use of
cancer antigens, such as WT1, MUC1, HER2, CA125 and others which will be the molecular targets of the activated CTL
(Cytotoxic T Lymphocytes). DC vaccine is used as a central core of the integrative medicine and will be supported by surgery,
radiation, chemotherapy, NK cell therapy, hyperthermia, high dose vitamin C, metronomic chemotherapy, Chinese herbal
medicine and dietary supplements.
Clinical Application
One hundred twenty seven in operable, advanced cancer patients with lung, gastrointestinal, hepatic, pancreatic, renal, breast,
ovarian and uterine as well as melanoma were treated with DC vaccine.
Syngeneic DCs were administered intradermally 5 to 8 times at 2 weeks intervals. The clinical response was evaluated according
to RECIST criteria.
Efficiency
Overall response rate was 23.6% and tumor control rate was 60.4%. Overall survival rate will be shown in some of these cancers
presented.
Adverse events were evaluated by grading the toxicity according to the common terminology criteria for adverse events (CTCAE)
version 4.0.Severe side effects of more than grade 2 were not observed.
Cancer genomics were analyzed in every patient underwent DC vaccine. Methylation of genes which were found before treatment
was disappeared after DC vaccine.
This indicates efficiency of DC vaccine genetically.
Conclusion
It was strongly indicated that the DC vaccine was safe and effective in patients with the inoperable cancer refractory to standard
treatment.
This report suggests DC vaccine will be the main stream for Integrative Oncology.
• 제3회 국제 통합 종양치료학회
2-3 December, 2011 at Conference room Chamber of Deputies in Rome & Hotel Boscolo Exedra Roma in Rome
|
